IP Library Granted Patent US 9,566,336
Granted Patent B2
US 9,566,336 · App. 14/444,338 · Granted Feb 14, 2017

In situ gelling drug delivery system

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,566,336
App. No.
14/444,338
Granted
Feb 14, 2017
Kind
B2
Abstract

The invention provides liquid controlled-release drug delivery compositions which gel upon injection into the body to form, in situ, controlled-release drug implants. The compositions of the invention feature a gel-forming polymer that is insoluble in water, a polyethylene glycol solvent in which the polymer is dissolved, and the drug substance to be delivered.

Claims (15)

1. A method for forming a polymeric sustained-release drug delivery gel in a subject, comprising injecting into the subject a drug delivery device comprising a fluid composition, wherein:

the device comprises a tube;

the fluid composition is positioned in the tube;

the fluid composition comprises a drug, a biocompatible and bioerodable poly(DL-lactide-glycolide) (PLGA) polymer, and a polyoxyethylene ether;

the polyoxyethylene ether serves as a solvent for the PLGA polymer; and

the composition forms a gel phase when said composition comes into contact with water or bodily fluids.

2. The method according to claim 1 , wherein the composition is co-injected with an aqueous fluid.

3. The method according to claim 2 , wherein the aqueous fluid is buffered saline.

4. The method according to claim 1 , wherein the device has at least one opening.

5. The method according to claim 1 , wherein the device is an open tube.

6. The method according to claim 1 , wherein the polyoxyethylene ether is polyethylene glycol (PEG).

7. The method according to claim 6 , wherein the average MW of the polyethylene glycol is between about 100 and about 6000.

8. The method according to claim 6 , wherein the average MW of the polyethylene glycol is between about 200 and about 400.

9. The method according to claim 1 , wherein the drug is a pegylated prodrug.

10. The method of claim 1 , wherein the release rate of the drug from the device is dependent on the surface area of the composition that is exposed to water or bodily fluids.

Assignments (8)
RELEASE OF SECURITY INTEREST Recorded Mar 14, 2022
From: CRG SERVICING LLC, AS ADMINISTRATIVE AGENT
To: EYEPOINT PHARMACEUTICALS, INC.; EYEPOINT PHARMACEUTICALS US, INC.; ICON BIOSCIENCE, INC.
Reel/Frame 059365/0112 →
CHANGE OF NAME Recorded Apr 2, 2019
From: PSIVIDA US, INC.
To: EYEPOINT PHARMACEUTICALS, INC.
Reel/Frame 049108/0700 →
SECURITY INTEREST Recorded Feb 13, 2019
From: EYEPOINT PHARMACEUTICALS, INC.; EYEPOINT PHARMACEUTICALS US, INC.; ICON BIOSCIENCE, INC.
To: CRG SERVICING LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 048329/0045 →
RELEASE OF SECURITY INTEREST Recorded Feb 13, 2019
From: SWK FUNDING LLC, AS AGENT
To: PSIVIDA CORP.; PSIVIDA US, INC.; ICON BIOSCIENCE, INC.
Reel/Frame 048329/0136 →
SECURITY INTEREST Recorded Apr 5, 2018
From: PSIVIDA CORP.
To: SWK FUNDING LLC, AS AGENT
Reel/Frame 045848/0670 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 15, 2014
From: SU, DONGLING; ASHTON, PAUL; CHEN, JIANBING
To: CONTROL DELIVERY SYSTEMS, INC.
Reel/Frame 033954/0854 →
MERGER Recorded Oct 15, 2014
From: CONTROL DELIVERY SYSTEMS, INC.
To: PSIVIDA INC.
Reel/Frame 033954/0888 →
CHANGE OF NAME Recorded Oct 15, 2014
From: PSIVIDA INC.
To: PSIVIDA US, INC.
Reel/Frame 034005/0685 →